Reported Earlier, Intra-Cellular Therapies Prices Public Offering Of 6,849,316 Common Shares At $73/Share
Reported Earlier, Intra-Cellular Therapies Prices Public Offering Of 6,849,316 Common Shares At $73/Share
此前報道，細胞內療法將6,849,316股普通股的公開發行定價爲每股73美元
All of the shares in the offering will be sold by Intra-Cellular Therapies, with gross proceeds to Intra-Cellular Therapies expected to be $500.0 million before deducting underwriting discounts and commissions and offering expenses.
此次發行的所有股份將由細胞內療法出售，在扣除承保折扣和佣金以及發行費用之前，細胞內療法的總收益預計爲5億美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。